Observational studyDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver2021
Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population.
Observational study in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- The association between ulcerative colitis and COVID-19 severity: a systematic review and meta-analysis systematic review.International journal of colorectal disease · 2023Pooled it
- Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis.Scientific reports · 2022Pooled it
- Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.International journal of colorectal disease · 2022Pooled it
- The Incidence and Clinical Characteristics of COVID-19 in Children With IBD During the Omicron Wave: A Single-Center Experience in China.Gastroenterology research and practice · 2025Article
- Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients.World journal of gastroenterology · 2023Review
- COVID-19: gastrointestinal and hepatobiliary manifestations.Human pathology · 2023Review
- The Impact of Inflammatory Bowel Diseases and Related Medications on COVID-19 Severity and Outcome: A Tertiary Referral Center Experience from Turkey.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- COVID-19 and inflammatory bowel disease crosstalk: From emerging association to clinical proposal.Journal of medical virology · 2022Review
- Pleiotropic Effects of Vitamin D in Patients with Inflammatory Bowel Diseases.Journal of clinical medicine · 2022Review
- Clinical Features and Outcomes of Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease and Spondyloarthropathies.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review.Vaccines · 2022Review
- Digestive System Involvement During Coronavirus Disease 2019; the Newest Clinical Features and Potential Mechanisms : Digestive System Involvements and COVID-19.Galen medical journal · 2022Review
- Observational
- Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study.Journal of Korean medical science · 2021Article
- Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD.Journal of the Canadian Association of Gastroenterology · 2021Article
- Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy.Journal of gastroenterology and hepatology · 2021Observational
- Risk, Course, and Effect of SARS-CoV-2 Infection in Children and Adults with Chronic Inflammatory Bowel Diseases.Children (Basel, Switzerland) · 2021Review
- COVID-19 and its effects on the digestive system.World journal of gastroenterology · 2021Review
- Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.Canadian journal of gastroenterology & hepatology · 2021Article
- How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.Frontiers in immunologyArticle
Corrections and comments
- Commented on by
Authors and funding
24 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is unclear whether patients with inflammatory bowel disease (IBD) are at increased risk of COVID-19.
objectivesThis observational study compared the prevalence of COVID-19 symptoms, diagnosis and hospitalization in IBD patients with a control population with non-inflammatory bowel disorders.
methodsThis multicentre study, included 2733 outpatients (1397 IBD patients and 1336 controls), from eight major gastrointestinal centres in Lombardy, Italy. Patients were invited to complete a web-based questionnaire regarding demographic, historical and clinical features over the previous 6 weeks. The prevalence of COVID-19 symptoms, diagnosis and hospitalization for COVID-19 was assessed.
results1810 patients (64%) responded to the questionnaire (941 IBD patients and 869 controls). IBD patients were significantly younger and of male sex than controls. NSAID use and smoking were more frequent in controls. IBD patients were more likely treated with vitamin-D and vaccinated for influenza. Highly probable COVID-19 on the basis of symptoms and signs was less frequent in the IBD group (3.8% vs 6.3%; OR:0.45, 95%CI:0.28-0.75). IBD patients had a lower rate of nasopharyngeal swab-PCR confirmed diagnosis (0.2% vs 1.2%; OR:0.14, 95%CI:0.03-0.67). There was no difference in hospitalization between the groups (0.1% vs 0.6%; OR:0.14, 95%CI:0.02-1.17).
conclusionIBD patients do not have an increased risk of COVID-19 specific symptoms or more severe disease compared with a control group of gastroenterology patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.